Last reviewed · How we verify

Naval Medical Research Center — Portfolio Competitive Intelligence Brief

Naval Medical Research Center pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tafenoquine prophylaxis Tafenoquine prophylaxis marketed 8-aminoquinoline antimalarial Plasmodium mitochondrial electron transport chain Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. London School of Hygiene and Tropical Medicine · 1 shared drug class
  2. Menzies School of Health Research · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Naval Medical Research Center:

Cite this brief

Drug Landscape (2026). Naval Medical Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/naval-medical-research-center. Accessed 2026-05-17.

Related